Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT05844462

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05844462
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05844462. Randomized; triple masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2027-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease
Acronym
ERASE PH-COPD
Condition
Chronic Obstructive Pulmonary Disease
Intervention (Drug)
Tadalafil
Intervention (Drug)
Placebo
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)

Record details

Record id
cardio:ct-nct05844462
Content hash
3f3be1124786566646dd95aca03e1d0dc13d8ad921320e2a592d05c4db019921